Related Experiment Video
Updated: Jun 20, 2026
Pre-Chiasmatic, Single Injection of Autologous Blood to Induce Experimental Subarachnoid Hemorrhage in a Rat Model
Published on: June 18, 2021
A multiparameter panel method for outcome prediction following aneurysmal subarachnoid hemorrhage
Natacha Turck1, Laszlo Vutskits, Paola Sanchez-Pena
1Biomedical Proteomics Research Group, Department of Structural Biology and Bioinformatics, Medical University Centre, DBSB/CMU, Rue Michel Servet, 1, 1211 Geneva 4, Switzerland. natacha.turck@unige.ch
This study developed a multiparameter panel to predict poor outcomes in aneurysmal subarachnoid hemorrhage (aSAH) patients. The panel, combining clinical scores and biomarkers, aids early identification of individuals at risk for irreversible brain damage.
Area of Science:
- Neuroscience
- Biomarkers
- Clinical Prognostics
Background:
- Predicting long-term brain damage in aneurysmal subarachnoid hemorrhage (aSAH) during the acute phase is challenging.
- Early identification of at-risk patients is crucial for timely intervention and improved outcomes.
Purpose of the Study:
- To develop a multiparameter prognostic panel for early outcome prediction in aSAH patients.
- To combine clinical scores with brain injury biomarkers for enhanced prognostic accuracy.
Main Methods:
- Prospective enrollment of 141 aSAH patients across two cohorts.
- Analysis of blood biomarkers (H-FABP, NDKA, UFD1, S100beta, troponin I) and clinical scores (WFNS, GOS).
- Development of a six-parameter panel using multivariate analysis.
Main Results:
- Blood levels of H-FABP, S100beta, and troponin I predicted unfavorable outcomes.
- A six-parameter panel (WFNS, H-FABP, S100beta, troponin I, NDKA, UFD-1) achieved ~70% sensitivity and 100% specificity for unfavorable outcomes when three parameters were elevated.
- This predictive accuracy was consistent across both patient cohorts.
Conclusions:
- A prognostic panel integrating clinical scores and specific biomarkers is valuable for identifying aSAH patients at high risk of poor outcomes.
- This tool can facilitate early risk stratification and management decisions in aSAH.
- The panel includes four brain injury proteins, one cardiac marker, and a clinical score.
